SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...

C ertainly, you know what playlist to blast when you want to make a baby, but do you know which sex position is best to get ...

So there we were, dead in the water about two miles offshore and about eight miles from the landing where we launched. There ...

Researchers from University of Athens and National Centre For Scientific Research “Demokritos” have reported preclinical data from a study that aimed to assess the novel cryptochrome-2 (CRY2) ...

During the first cycle, Musoki lost eight chicks out of 150 chicks, which had diarrhoea. Despite this, she sold the remaining ...

Sold mainly in North America and India, the Venue comes in two lengths so as to slip beneath a tax category in the latter market: the Chennai-built model is 3,995 mm long or 45 mm shorter than the ...

Researchers identify distinct molecular and immune profiles that impact the prognosis of patients with metastatic pancreatic ductal adenocarcinoma.

This is something that's been widely appreciated but broadly overlooked when it comes to thinking about how tissues deal with ...

Gut microbiota-derived phenylacetylglutamine accelerates aging by driving cellular senescence through mitochondrial ...

Having a ready supply of rechargeable AA batteries on hand could keep hundreds of alkaline cells out of landfill.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.